TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Genomic Health Announces Six New Studies Including Four Oral Presentations Covering Breast, Colon and First Study in Renal Cancer Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire) Genomic Health, Inc. today announced that the company will present results from six separate studies at the American Society of Clinical Oncology Annual Meeting, taking place June 4-8, 2010 at McCormick Place in Chicago.  The studies include four oral presentations covering breast, colon and renal cancers.  The company markets the widely-adopted Oncotype DX® breast cancer test, which is clinically validated to predict chemotherapy benefit as well as the likelihood of recurrence in early-stage breast cancer patients.  In addition, the company launched the Oncotype DX colon cancer test in January 2010. us.rd.yahoo.com |
Gilead Sciences, Inc. Q2 2010 Earnings Call Transcript Gilead Sciences, Inc. (GILD)Q2 2010 Earnings Call TranscriptJuly 20, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Pain Relief Patches Take Hold in U.S. Pain patches, widely used instead of oral painkillers outside the U.S., could help Americans avoid uncomfortable or dangerous side effects that often result from popping aspirin and other pills, doctors say. online.wsj.com |
Novartis to Pay $422.5 Million to Settle Allegations: Biotech's Latest Tribulations The Burrill Report submits: Novartis Pharmaceuticals (NVS) said it reached a $422.5 million agreement with the U.S. Attorney's Office for the Eastern District of Pennsylvania regarding civil and criminal allegations of the off-label promotion of Trileptal, as well as civil allegations relating to five other products. Novartis said the payments are in line with provisions made for a potential agreement. As part of the settlement, the company will enter a Corporate Integrity Agreement with Office of the Inspector General. It will require the company to implement for five years additional compliance-related measures, which include additional monitoring, auditing, training, education, reporting and disclosures.Johnson & Johnson (JNJ) officials told a Congressional committee that it had misled consumers and regulators in its effort to quietly remove its Motrin painkiller from the market, Reuters reported. J&J is facing a criminal probe. During the hearing, the lawmakers charged that the company had placed profits over the welfare of its customers. The company, which had sought to buy back its supply of Motrin through the use of contractors posing as customers, said its McNeil unit should have alerted stores and the U.S. Food and Drug Administration to the 2009 recall.Complete Story » seekingalpha.com |
LSI Industries CEO Discusses F1Q2011 Results - Earnings Call Transcript LSI Industries, Inc. (LYTS)F1Q2011 (Qtr End 09/30/10) Earnings Conference CallOctober 21, 2010 3 PM ETComplete Story » seekingalpha.com |